Anti-Müllerian hormone signaling is influenced by Follistatin 288, but not 14 other transforming growth factor beta superfamily regulators

Molecular Reproduction and Development
Yui KawagishiIan S McLennan

Abstract

The hypothesis that, in contrast to other transforming growth factor-beta (TGFβ) superfamily ligands, the dose-response curve of Anti-Müllerian hormone (AMH) is unmodulated was tested by examining whether known TGFB superfamily modulators affect AMH signaling, using a P19/BRE luciferase reporter assay. AMHCand AMHN,Cactivated the reporter with an EC50 of approximately 0.5 nM. Follistatins (FS) produced concentration-dependent increases in AMHC- and AMHN,C-initiated reporter activity, with FS288 being more potent than FS315; however, the maximum bioactivity of AMH was not altered by either follistatin. Thirteen other TGFβ regulators (Chordin, Chordin-like 1, Chordin-like 2, Differential screening-selected gene aberrative in neuroblastoma [DAN], Decorin, Endoglin, Follistatin-like 1, Follistatin-like 3, Follistatin-like 4, Noggin, α2 macroglobulin, TGFβ receptor 3, Von Willebrand factor C domain-containing 2) had little or no effect. Surface plasmon resonance analysis showed no significant association between FS288 and AMHC, suggesting that FS288 indirectly regulates AMH signaling. Activin A, a direct target of FS288, did not itself induce reporter activity in P19 cells, but did prevent the FS288-induced increase in AMH signaling...Continue Reading

References

Feb 1, 1990·The American Review of Respiratory Disease·E A CatlinP K Donahoe
Feb 11, 2003·Advances in Experimental Medicine and Biology·David T MacLaughlin, Patricia K Donahoe
Jun 18, 2003·Cell·Yigong Shi, Joan Massagué
Oct 9, 2004·The Journal of Clinical Endocrinology and Metabolism·Alan L SchneyerPatrick M Sluss
Nov 2, 2005·Proceedings of the National Academy of Sciences of the United States of America·Pei-Yu WangIan S McLennan
Feb 17, 2006·The EMBO Journal·Adrian E HarringtonMarko Hyvönen
Mar 15, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rafael Pieretti-VanmarckeDavid T MacLaughlin
Apr 11, 2009·Proceedings of the National Academy of Sciences of the United States of America·Pei-Yu WangIan S McLennan
Oct 27, 2009·Development·Aristidis Moustakas, Carl-Henrik Heldin
Oct 27, 2009·Development·David UmulisSeth S Blair
Sep 24, 2010·Molecular Endocrinology·Nathalie di ClementeRichard L Cate
Jan 11, 2012·Nature Reviews. Endocrinology·Jenny A VisserAxel P N Themmen
Sep 21, 2012·Nature Reviews. Molecular Cell Biology·Joan Massagué
Oct 10, 2012·Seminars in Reproductive Medicine·Nathalie JossoJean-Yves Picard
Sep 21, 2013·American Journal of Physiology. Endocrinology and Metabolism·Michael W Pankhurst, Ian S McLennan
Mar 13, 2014·Reproduction : the Official Journal of the Society for the Study of Fertility·Eric E NilssonMichael K Skinner
Jul 15, 2015·The Journal of Endocrinology·Ian S McLennan, Michael W Pankhurst
Aug 19, 2015·Vitamins and Hormones·Barbara Mulloy, Chris C Rider

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.